Investing in another company's drug to advance your own ↗
Use SAFFRON to consider when an existing drug can stay in a later regimen.
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
Commercialization · TOPIC v1
Why keep a drug after resistance emerges?
For which resistance profiles is it worth retaining EGFR inhibition and adding a MET inhibitor?
Read article → Why keep a drug after resistance emerges?
2026-11-04 16:54:52.561 UTC · Last recorded update
CURRENT READING
In phase 3 SAFFRON, 338 selected patients had median progression-free survival of 7.6 months with the combination and 5.4 months with chemotherapy.
Recorded editorial state, not a maturity score
- Phase 3 resultsRecorded
- Testing and uptakeUnverified
New question opened · v1
Recorded phase 3 results for a combination matched to a resistance mechanism.
Permanent link to this revision ↗01 / WHAT WE TRACK
For which resistance profiles is it worth retaining EGFR inhibition and adding a MET inhibitor?
02 / EVIDENCE & TECHNOLOGY
EGFR inhibition, MET inhibition and resistance biomarkers
03 / EDITORIAL READING
A drug targeting a bypass pathway can give clinicians a reason to keep an existing drug in a later regimen.
04 / WHAT REMAINS UNKNOWN
The trial compared a specific chemotherapy regimen in patients selected for high MET.
05 / NEXT CHECK
Track the authorized population, testing criteria and the regimen’s place among later-line options.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDSelecting for the resistance mechanism could make dual pathway inhibition a treatment option.
What would change our view: Reassess adoption if the benefits and burdens compare unfavorably with other later-line therapies.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREOsimertinib ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTURESavolitinib ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREMET ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v1 · 2026-11-04 16:54:52.561 UTCNew question opened
Recorded phase 3 results for a combination matched to a resistance mechanism.
Reading at the time: In phase 3 SAFFRON, 338 selected patients had median progression-free survival of 7.6 months with the combination and 5.4 months with chemotherapy.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
Phase 2 trial ↗
Clinical Lung Cancer · 2025-10-22 · peer-reviewed-trial
Results announcement ↗
AstraZeneca · 2026-10-25 · company-announcement
Trial overview ↗
AstraZeneca · · trial-description
NEJM trial report ↗
New England Journal of Medicine · 2026-10-25 · peer-reviewed-trial